Clinical trial
A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
NCT00127920 is registered in ClinicalTrials.gov with Gynecologic Oncology Associates as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
- Lead sponsor
- Gynecologic Oncology Associates
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- October 31, 2012
- Enrollment
- 20 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.